Benefits of T-DXd for HER2-Low Breast Cancer Continue.

Published Date: 11 Nov 2023

When compared to physician's choice of treatment (TPC), trastuzumab deruxtecan (T-DXd) offered patients with advanced breast cancer and low HER2 expression a sustained clinically meaningful improvement.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

When Should Immunocompromised Individuals Receive a COVID Booster?

2.

Home Screening Appeals to Women Facing Healthcare Barriers

3.

Quality of Life Similar With Proton Beam Therapy vs IMRT for Prostate Cancer

4.

Prolonged Screen Time Linked to Sleep Issues in Preschoolers

5.

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot